Indo-Bangla Pharmaceuticals (DHA:IBP) EBIT: BDT Mil (TTM As of . 20)


DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT15.30
View Full Analysis

What is Indo-Bangla Pharmaceuticals EBIT?

Indo-Bangla Pharmaceuticals DHA:IBP +1.32% 32 EBIT is BDT Mil as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100.

Indo-Bangla Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in . 20 was BDT0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Indo-Bangla Pharmaceuticals  (DHA:IBP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Indo-Bangla Pharmaceuticals's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Indo-Bangla Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Indo-Bangla Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals EBIT Related Terms

Indo-Bangla Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Indo-Bangla Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals EBIT Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
EBIT

Indo-Bangla Pharmaceuticals Semi-Annual Data
EBIT

DHA:IBP vs : EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indo-Bangla Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Indo-Bangla Pharmaceuticals's EV-to-EBIT falls into.


DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in . 20 was BDT Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of BDT Mil mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a EBIT of BDT Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Indo-Bangla Pharmaceuticals.
Is Indo-Bangla Pharmaceuticals' EBIT too high?
Indo-Bangla Pharmaceuticals' current EBIT is BDT Mil. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' EBIT compare to ?
Indo-Bangla Pharmaceuticals' EBIT of BDT Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Indo-Bangla Pharmaceuticals. Indo-Bangla Pharmaceuticals's current EBIT is BDT Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current EBIT of BDT Mil. The current EBIT is BDT Mil. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current EBIT is BDT Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT15.30
Price